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Identity 
Other names: ATF3deltaZip2; ATF3deltaZip2c; 
ATF3deltaZip3 




The ATF3 gene spans a region of 55 kb and has two 
major transcription start sites, each designated P1 and 
P2, respectively. The P1 and P2 transcripts differ in the 
first exon but share common exons 2, 3, and 4 encodi g 
the same protein sequence. 
Transcription 
Transcribed from centromere to telomere orientation. 
The P1 and P2 promoters are differentially activated by 







atf3 protein represents one of the 53 basic leucine 
zipper (b-Zip) transcription factors in human and is 
composed of 181 amino acids with putative basic 
leucine zipper structure. The leucine zipper region is 
responsible for homo- or heterodimer formation with 
other member of bZip family proteins. One study 
reported that transcriptional activation or repression 
activity is located at both N- or C-terminal region, but 
the detailed mechanism of those activity remains 
elusive. 
Description 
The P1 and P2 transcripts give rise to atf3 proteins of 
an identical sequence. These transcripts, however, ar  
differentially spliced to give rise to full length and 
deltaZip or deltaZip2 proteins lacking the C-terminal 
dimerization domain. 
Expression 
ATF3 is expressed ubiquitously but its level is 
maintained low in the absence of cellular stresses.  
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Upon exposure to various conditions, such as hypoxia, 
DNA damaging agents (MMS, 5-FU, etoposide, 
ionizing radiation, UV irradiation), heat shock, cold 
shock, nutrient starvation, and serum stimulation, 
ATF3 is rapidly induced by transcriptional activation. 
Known upstream regulators of ATF3 include ATF4, 
HIF-1a, C/EBPb, and p53. 
Localisation 
ATF3 proteins are localized in the nucleus. 
Function 
ATF3 is a member of the CREB/ATF family of 
transcription factors and both homodimerize and 
heterodimerize with other members of CREB/ATF 
family, including C/EBPg, CHOP/DDIT3, ATF2, Jun, 
JunB, p21SNFT/JDP1, and Nrf2/NFE2L2. 
ATF3 and various heterodimers containing ATF3 has 
been shown to bind to a consensus cAMP response 
element (5'-GTGACGT[AC][AG]-3') with varying 
affinities in vitro. ATF3 also interacts with other DNA 
binding proteins such as Elk1, Sp1, and Egr1 which 
might recruit ATF3 to promoters indirectly. 
Increasing number of genes have been shown to be 
regulated by ATF3 (currently about 40 target genes ar  
known). ATF3 plays an important role in repressing IL-
6, IL-12, and other cytokine genes downstream of Toll-
like receptor 4 (TLR4) thereby providing a negative 
feedback to contain excessive inflammatory responses. 
A splice variant of ATF3 (dZip2) forms complex with 
p65 subunit of NF-kB and inhibits recruitment of CBP, 
thus repressing inhibitors of apoptosis (IAPs) genes. 
ATF3 can also interfere with Nrf2-mediated gene 
activation by causing dissociation of CBP from Nrf2. 
Thus, it is likely that ATF3 is a regulator of stress 
response. 
ATF3 is one of immediate early response genes and 
plays role in determining cell fate. However, its 
biological function of ATF3 in vivo remains largely 
elusive since targeted disruption of the ATF3 gene 
causes no obvious phenotype. Studies mostly carried 
out in vitro using established cancer cell lines show that 
ATF3 has dual functions in promoting either cell death 
or cell survival under different conditions. On one 
hand, the ATF3 gene is overexpressed in a large 
fraction of cancers including solid tumors in the br ast, 
lungs, prostate, colon or Hodgkin Reed-Sternberg cells, 
suggesting that ATF3 may promote proliferation and/or 
survival of cancer cells. On the other, expression of  
ATF3 has been shown to cause cell death of various 
cancer cell lines in response to DNA damage, UV, or 
various anti-cancer drugs. 
ATF3 is also proposed to be a causative gene in 
hypospadia. 
Homology 
ATF3 share a highly homologous leucine zipper 
domain with other CREB/ATF family members. ATF3 
has been found widely in vertebrates and there is also a 
paralogue of ATF3 called JDP2 which differ from 
ATF3 in the C-terminal region. Higher vertebrates have 
both ATF3 and JDP2 homologues, whereas Ciona 
intestinalis has only one copy of either ATF3 or JDP2 
(it is not clear which). Drosophila melanogaster A3-3 
share 55% identity with aa 81-149 of human ATF3 and







Solid tumors and Hodgkin's disease 
Note 
ATF3 is overexpressed in many cancer cells. 
Disease 
ATF3 is overexpressed in a large fraction of various 
cancers including solid tumors in the breast, lungs, 
pancreas, and colon ATF3 is hyperactivated in most 
cells in Hodgkin's disease. 
Overexpression of ATF3 in cancer cells have been 
proposed to promote proliferation and inhibit cell 
death. 
Prognosis 
Over-expression of ATF3 in cancer cells correlates 
with higher incidence of metastasis and poor prognosis 

















ATF3 is a major mediator of activated ras and express 
of ATF3 alone can cause mitogen-induce MAP kinase 
activation. ATF3 is overexpressed in a large fraction of 




Obese conditions activate the ATF3 gene in adipocytes 
thereby causing repression of GLUT4 gene and 













ATF3 is up-regulated in the penile skin tissues of b ys 
with hypospadias, suggesting a role for this 
transcription factor in the development of this 
abnormality. Because the etiology of hypospadias may
include exposure to estrogenic compounds, the 
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